Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats

Application of simulation to preclinical PK-PD study design

Gregor Bender, James Gosset, Jeff Florian, Keith Tan, Mark Field, Scott Marshall, Joost Dejongh, Robert Bies, Meindert Danhof

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenafil for the treatment of neuropathic pain. The focus of this study was to determine the influence of sildenafil on the pharmacokinetics (PK) of pregabalin with the objective of informing the design of a quantitative pharmacodynamic (PD) study. Methods: The pharmacokinetics were determined in rats following 2-hr intravenous infusions of pregabalin at doses of 4 mg/kg/hr and 10 mg/kg/hr with and without a sildenafil bolus (2.2 mg) and steady state infusion (12 mg/kg/hr for 6 h). This PK model was utilized in a preclinical trial simulation with the aim of selecting the optimal sampling strategy to characterize the PK-PD profile in a future study. Eight logistically feasible PK sampling strategies were simulated in NONMEM and examined through trial simulation techniques. Results: A two-compartment population PK model best described pregabalin pharmacokinetics. Significant model covariates included either a binary effect of sildenafil administration (30.2% decrease in clearance) or a concentration-dependent effect due to sildenafil's active metabolite. Conclusions: Analysis of simulations indicated that three post-PD samples had the best cost/benefit ratio by providing a significant increase in the precision (and minor improvement in bias) of both PK and PD parameters compared with no PK sampling.

Original languageEnglish (US)
Pages (from-to)2259-2269
Number of pages11
JournalPharmaceutical Research
Volume26
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Pharmacodynamics
Pharmacokinetics
Rats
Population
Sampling
Pregabalin
Sildenafil Citrate
Neuralgia
Metabolites
Intravenous Infusions
Cost-Benefit Analysis

Keywords

  • Neuropathic pain
  • Optimal sampling
  • Synergistic interaction
  • Trial simulation

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Organic Chemistry
  • Molecular Medicine
  • Pharmacology (medical)
  • Biotechnology
  • Pharmacology

Cite this

Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats : Application of simulation to preclinical PK-PD study design. / Bender, Gregor; Gosset, James; Florian, Jeff; Tan, Keith; Field, Mark; Marshall, Scott; Dejongh, Joost; Bies, Robert; Danhof, Meindert.

In: Pharmaceutical Research, Vol. 26, No. 10, 10.2009, p. 2259-2269.

Research output: Contribution to journalArticle

Bender, Gregor ; Gosset, James ; Florian, Jeff ; Tan, Keith ; Field, Mark ; Marshall, Scott ; Dejongh, Joost ; Bies, Robert ; Danhof, Meindert. / Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats : Application of simulation to preclinical PK-PD study design. In: Pharmaceutical Research. 2009 ; Vol. 26, No. 10. pp. 2259-2269.
@article{030417d6873f46a28d0970811e58cb11,
title = "Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: Application of simulation to preclinical PK-PD study design",
abstract = "Purpose: Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenafil for the treatment of neuropathic pain. The focus of this study was to determine the influence of sildenafil on the pharmacokinetics (PK) of pregabalin with the objective of informing the design of a quantitative pharmacodynamic (PD) study. Methods: The pharmacokinetics were determined in rats following 2-hr intravenous infusions of pregabalin at doses of 4 mg/kg/hr and 10 mg/kg/hr with and without a sildenafil bolus (2.2 mg) and steady state infusion (12 mg/kg/hr for 6 h). This PK model was utilized in a preclinical trial simulation with the aim of selecting the optimal sampling strategy to characterize the PK-PD profile in a future study. Eight logistically feasible PK sampling strategies were simulated in NONMEM and examined through trial simulation techniques. Results: A two-compartment population PK model best described pregabalin pharmacokinetics. Significant model covariates included either a binary effect of sildenafil administration (30.2{\%} decrease in clearance) or a concentration-dependent effect due to sildenafil's active metabolite. Conclusions: Analysis of simulations indicated that three post-PD samples had the best cost/benefit ratio by providing a significant increase in the precision (and minor improvement in bias) of both PK and PD parameters compared with no PK sampling.",
keywords = "Neuropathic pain, Optimal sampling, Synergistic interaction, Trial simulation",
author = "Gregor Bender and James Gosset and Jeff Florian and Keith Tan and Mark Field and Scott Marshall and Joost Dejongh and Robert Bies and Meindert Danhof",
year = "2009",
month = "10",
doi = "10.1007/s11095-009-9942-y",
language = "English (US)",
volume = "26",
pages = "2259--2269",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats

T2 - Application of simulation to preclinical PK-PD study design

AU - Bender, Gregor

AU - Gosset, James

AU - Florian, Jeff

AU - Tan, Keith

AU - Field, Mark

AU - Marshall, Scott

AU - Dejongh, Joost

AU - Bies, Robert

AU - Danhof, Meindert

PY - 2009/10

Y1 - 2009/10

N2 - Purpose: Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenafil for the treatment of neuropathic pain. The focus of this study was to determine the influence of sildenafil on the pharmacokinetics (PK) of pregabalin with the objective of informing the design of a quantitative pharmacodynamic (PD) study. Methods: The pharmacokinetics were determined in rats following 2-hr intravenous infusions of pregabalin at doses of 4 mg/kg/hr and 10 mg/kg/hr with and without a sildenafil bolus (2.2 mg) and steady state infusion (12 mg/kg/hr for 6 h). This PK model was utilized in a preclinical trial simulation with the aim of selecting the optimal sampling strategy to characterize the PK-PD profile in a future study. Eight logistically feasible PK sampling strategies were simulated in NONMEM and examined through trial simulation techniques. Results: A two-compartment population PK model best described pregabalin pharmacokinetics. Significant model covariates included either a binary effect of sildenafil administration (30.2% decrease in clearance) or a concentration-dependent effect due to sildenafil's active metabolite. Conclusions: Analysis of simulations indicated that three post-PD samples had the best cost/benefit ratio by providing a significant increase in the precision (and minor improvement in bias) of both PK and PD parameters compared with no PK sampling.

AB - Purpose: Preliminary evidence has suggested a synergistic interaction between pregabalin and sildenafil for the treatment of neuropathic pain. The focus of this study was to determine the influence of sildenafil on the pharmacokinetics (PK) of pregabalin with the objective of informing the design of a quantitative pharmacodynamic (PD) study. Methods: The pharmacokinetics were determined in rats following 2-hr intravenous infusions of pregabalin at doses of 4 mg/kg/hr and 10 mg/kg/hr with and without a sildenafil bolus (2.2 mg) and steady state infusion (12 mg/kg/hr for 6 h). This PK model was utilized in a preclinical trial simulation with the aim of selecting the optimal sampling strategy to characterize the PK-PD profile in a future study. Eight logistically feasible PK sampling strategies were simulated in NONMEM and examined through trial simulation techniques. Results: A two-compartment population PK model best described pregabalin pharmacokinetics. Significant model covariates included either a binary effect of sildenafil administration (30.2% decrease in clearance) or a concentration-dependent effect due to sildenafil's active metabolite. Conclusions: Analysis of simulations indicated that three post-PD samples had the best cost/benefit ratio by providing a significant increase in the precision (and minor improvement in bias) of both PK and PD parameters compared with no PK sampling.

KW - Neuropathic pain

KW - Optimal sampling

KW - Synergistic interaction

KW - Trial simulation

UR - http://www.scopus.com/inward/record.url?scp=69949133676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949133676&partnerID=8YFLogxK

U2 - 10.1007/s11095-009-9942-y

DO - 10.1007/s11095-009-9942-y

M3 - Article

VL - 26

SP - 2259

EP - 2269

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 10

ER -